Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma

Trial Profile

Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 18 Dec 2017 Last checked against EudraCT record.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Positive final results presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to an Erytech Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top